SUNSET, La., July 29, 2015 (GLOBE NEWSWIRE) -- A new study shows patients with the MTHFR C677T/A1298C enzyme polymorphism significantly benefit from reduced B vitamin therapy, marketed under the prescription trade name, EnLyte. 60-90% of the US population have the MTHFR enzyme polymorphism, which hinders the metabolism of critical B vitamins and cofactors.
MTHFR polymorphism leads to impaired folate metabolism and is directly correlated with elevated homocysteine (hyperhomocysteinemia). Homocysteine is a toxic amino acid linked to psychiatric conditions such as depression, bipolar disorder, anxiety, and schizophrenia, as well as neural tube defects, repeated miscarriage, infertility, PTSD, migraine with aura, cardiovascular disease, stroke, age related cognitive decline, autism, Parkinson's, chronic fatigue syndrome, and fibromyalgia.
"Reduced B Vitamin Therapy in MTHFR C677T/A1298C Patients with Major Depressive Disorder- Clinical Response Correlates with Homocysteine Reduction: A Double-Blind, Placebo-Controlled Study" was conducted by Arnie Mech, MD, Mech Healthcare Associates, with collaboration by Andrew Farah, MD, Chief of Psychiatry, High Point Division of UNC Healthcare.
330 confirmed MTHFR polymorphic patients were randomized to receive either placebo or EnLyte Gelcaps as monotherapy once daily for 8 weeks. Homocysteine levels were drawn at baseline and 8 weeks.
The EnLyte group showed a separation from placebo by week 2 of homocysteine levels. Homocysteine levels were reduced 33% by week 8 in the EnLyte group. In the placebo group, homocysteine levels continued to increase over the course of the study. The EnLyte group reported a side effect profile comparable to placebo.
"Since higher than normal homocysteine levels are associated with many neurodegenerative disorders and congenital conditions, the use of reduced B vitamins (EnLyte) for neuroprotection and prenatal implications are obvious areas of future study." Andrew Farah, MD
About EnLyte
EnLyte is an advanced generation folate therapy by prescription, FDA regulated to treat conditions related to hyperhomocysteinemia and/or suboptimal folate levels including as monotherapy or adjunctive therapy to an SSRI/SNRI in depression. EnLyte contains L-methylfolate magnesium, folinic acid, folacin, brain-ready cofactors of b1, b2, b3, b6, b12, betaine, zinc, magnesium, vitamin c, and PS gold omega 3s. EnLyte is pregnancy category A and safe for use in children. EnLyte is paid by many insurance plans at a reasonable copay and available through cash pay mail order for $58 per month. For more information or licensed prescriber samples, contact EnLyte Customer Care, 985.788.7755 or visit www.EnLyteRx.Com.